2024年5月10日 · NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, which we believe has the potential to be the only “Single-Day CRS” CAR-T, targeting AL...

2024年4月18日 · NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications.

2024年4月29日 · NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis. Learn more at immixbio.com and www.BeProactiveInAL.com .

2024年5月10日 · At the NXC-201 ASGCT 2024 late-breaking oral presentation, data were presented from 13 relapsed/refractory AL amyloidosis patients (including 3 new patients) in the ongoing Phase 1b/2a NEXICART-1...

2024年4月15日 · We believe NXC-201 (formerly HBI0101) is the only “Single-Day CRS” CAR-T cell therapy that is uniquely suited to target AL Amyloidosis and other autoimmune diseases.

• NXC -201 is a next generation chimeric antigen receptor (CAR) T cell (CAR T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA) • High Overall Response Rates in AL Amyloidosis and Multiple Myeloma

2024年5月10日 · NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, which we believe has the potential to be the only “Single-Day CRS” CAR-T, targeting AL Amyloidosis and other autoimmune diseases.

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.

2024年4月18日 · “We are on track to dose relapsed/refractory AL Amyloidosis NXC-201 patients at our New York City lead site and other leading U.S. sites in mid-2024. U.S. site clinical trial agreements have been...

2024年4月15日 · NEXICART-1 (NCT04720313) is an ongoing Phase 1b/2a, open-label study evaluating the safety and efficacy of NXC-201 (formerly HBI0101), in adults with relapsed/refractory multiple myeloma and AL...